Figure 2
From: Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment
ASO-T3 reduces adiposity in obesity. (a–f) Caloric intake (a), body weight gain (b), percent fat and lean mass (c), delta fat mass (d), delta lean mass (e) and weight of epididymal (eWAT), inguinal (iWAT) and brown (BAT) adipose tissue (f) in high-fat diet fed mice treated with PBS control, T3, NNMT-ASO-T3 (NAT3) or ApoB-ASO-T3 (AAT3). (g–k) Metabolic cages studies. Oxygen consumption (g,h) and CO2 production (i) normalized to lean mass, respiratory quote (j) and locomotor activity (k) in control, T3, NAT3 and AAT3-treated mice. (l) Glucose; (m) insulin levels in control, T3, NAT3 and AAT3-treated mice. n = 4–6 per group; *p < 0.05 vs controls (Con), #p < 0.05 vs T3.
